1 not yet recruiting, 1 unknown. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
Follow PE regimen: new trials by email Literature Review of PE regimen trials Research Report on PE regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel - Solid Tumor Cancer, Chemotherapy Induced Neutropenia | Not applicable | Not yet recruiting | Shandong Cancer Hospital and Institute | 200 | 2024-10-10 | 2024-10-18 |
| Molecular Phenotype Changes and Personalized Treatment for CRPC Docetaxel & Prednisone, DP & Targeted drugs, cisplatin & Etoposide - Hormone Refractory Prostate Cancer | Not applicable | Unknown | Tianjin Medical University Cancer Institute and Hospital | 150 | 2014-06-01 | 2014-08-05 |
Shandong Cancer Hospital and Institute (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (2)
JinMing Yu, Phd (1) · Wang HaiTao, Ph.D (1)